Baird Medical to Showcase Minimally Invasive Thyroid Solutions at Upcoming US Clinical Conferences

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) will showcase its minimally invasive Microwave Ablation (MWA) thyroid solutions at three U.S. clinical conferences in late Feb–March 2026. The company plans live demonstrations and clinician engagement to promote needle-based treatments for benign thyroid nodules that avoid traditional surgery and scarring.

Events: NASOIE Feb 27–28 Miami, NASIT Mar 6–7 Portland, ISITES Mar 11–13 Washington, D.C.

News Market Reaction – BDMD

+12.32% 4.3x vol

79 alerts

+12.32% Session close to close

+67.1% Peak Tracked

-9.6% Trough Tracked

$89.61M Market Cap

4.3x Rel. Volume

In the Feb 19 session, BDMD gained 12.32%, reflecting a significant positive market reaction. Argus tracked a peak move of +67.1% during that session. Argus tracked a trough of -9.6% from its starting point during tracking. Our momentum scanner triggered 79 alerts that day, indicating high trading interest and price volatility. Trading volume was very high at 4.3x the daily average, suggesting strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +12.3% in the session following this news. A strong positive reaction aligns with B...

Analysis

The stock surged +12.3% in the session following this news. A strong positive reaction aligns with BDMD’s ongoing push to expand minimally invasive thyroid MWA adoption. The stock traded at $1.38, up 9.52%, with volume at 1.28x its 20-day average. Recent history shows mixed alignment between upbeat commercialization news and price moves, so conference-driven enthusiasm could face pressure from broader regulatory and resale overhangs disclosed in recent filings and from profit-taking after sharp single-day gains.

Key Figures

Clinical conferences: 3 conferences NASOIE dates: February 27–28 NASIT dates: March 6–7 +1 more

4 metrics

Clinical conferences 3 conferences Number of major clinical conferences BDMD will attend this quarter

NASOIE dates February 27–28 North American Society for Interventional Endocrinology conference schedule

NASIT dates March 6–7 North American Society for Interventional Thyroidology conference schedule

ISITES dates March 11–13 International Society of Innovative Technologies for Endocrine Surgery conference schedule

Historical Context

5 past events · Latest: Feb 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 11	US hospital launch	Positive	-7.6%	First benign thyroid tumor ablation at Bakersfield Memorial advances US roadmap.
Feb 09	Clinical education push	Positive	+9.7%	Training programs in US and Japan to accelerate global MWA adoption.
Jan 28	Gynecology masterclass	Positive	+6.9%	Shanghai masterclass expands physician training in women’s health MWA applications.
Jan 26	Strategic partnership	Positive	+0.0%	Stonewood Key Capital deal uses Hainan Free Trade Port for global expansion.
Jan 20	JPM conference	Positive	-0.9%	Engagements at J.P. Morgan conference on US growth and MWA thyroid strategy.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent BDMD news has been consistently positive on commercialization and education, with mixed price reactions; several upbeat operational milestones saw flat or negative moves, suggesting occasional divergence between news tone and short-term trading.

Recent Company History

This announcement continues a series of commercialization and education milestones. Since Jan 20, 2026, BDMD has highlighted investor outreach at the J.P. Morgan Healthcare Conference, a strategic partnership with Stonewood Key Capital to use the Hainan Free Trade Port, a gynecology microwave ablation masterclass in Shanghai, and US and Japan clinical training initiatives. The Feb 11 Bakersfield Memorial Hospital launch marked the first benign thyroid tumor ablation in central California. Today’s US conference participation further builds clinician awareness of its thyroid MWA platform.

Key Terms

microwave ablation (mwa), benign nodules, interventional endocrinology, interventional thyroidology, +1 more

5 terms

microwave ablation (mwa) medical

"a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced"

Microwave ablation (MWA) is a minimally invasive medical procedure that uses focused microwave energy to heat and destroy unwanted tissue, such as tumors or lesions, without open surgery. Think of it like using a tiny, precise microwave oven inside the body to remove a problem area; for investors, MWA matters because its effectiveness, safety, costs, and adoption influence demand for related devices, hospital procedures, reimbursement and potential market growth.

benign nodules medical

"treats benign nodules without the need for traditional surgery or scarring."

Benign nodules are non-cancerous lumps or growths that can appear in organs such as the thyroid, lungs or liver; they do not invade nearby tissue or spread to other parts of the body. For investors, they matter because their diagnosis, monitoring or removal drives demand for medical tests, treatments and procedures, can influence clinical trial outcomes or regulatory decisions, and affects cost forecasts and revenue potential for healthcare companies—think of them as harmless bumps that still require attention and resources.

interventional endocrinology medical

"North American Society for Interventional Endocrinology (NASOIE)"

Interventional endocrinology is a medical subspecialty that treats hormone-producing glands and related conditions using minimally invasive procedures—such as targeted injections, ablations or catheter-based techniques—rather than open surgery or only drugs. For investors, it matters because these procedures create demand for specialized devices, outpatient services and new reimbursement pathways, so advances or approvals can shift revenue prospects much like a new tool changing how plumbers fix a pipe without tearing down the wall.

interventional thyroidology medical

"North American Society for Interventional Thyroidology (NASIT)"

Interventional thyroidology is the medical field that treats thyroid problems using minimally invasive procedures—such as image-guided needle therapies, thermal or chemical ablation, and targeted drainages—instead of open surgery. For investors, it matters because these procedures drive demand for specialized devices, training, and outpatient services, can lower costs and recovery time for patients, and influence reimbursement and market growth for companies supplying the equipment and clinics.

endocrine surgery medical

"International Society of Innovative Technologies for Endocrine Surgery (ISITES)"

Surgical procedures on the body's hormone-producing glands—most commonly the thyroid, parathyroid, adrenal glands and certain pancreas tumors—aimed at removing disease, correcting hormone imbalances or diagnosing conditions. For investors, endocrine surgery matters because it drives demand for specialized devices, imaging, hospital services and follow-up therapies; like repairing a malfunctioning thermostat in a house, successful surgery can restore balance and reduce long-term treatment costs, affecting healthcare revenues and reimbursement patterns.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Feb. 19, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its participation for three major clinical conferences this quarter. These events are pivotal to the company's expansion, providing U.S. clinicians direct access to its innovative needle-based therapies for thyroid conditions.

Baird Medical will join top interventionalists and surgeons to demonstrate how its proprietary technology treats benign nodules without the need for traditional surgery or scarring.

The Company will present its solutions at:

• North American Society for Interventional Endocrinology (NASOIE)
  
  
• February 27 – 28 | Miami, FL
  
  
• North American Society for Interventional Thyroidology (NASIT)
  
  
• March 6 – 7 | Portland, OR
  
  
• International Society of Innovative Technologies for Endocrine Surgery (ISITES)
  
  
• March 11 – 13 | Washington, D.C.

"We are on the ground at these events to show physicians exactly what our technology can do for their patients," said Mark Saxton, CEO of Baird Medical (US). "As minimally invasive options become the standard of care, building these direct relationships with the clinical community is how we drive adoption and grow our presence in the US market."

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. 

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-to-showcase-minimally-invasive-thyroid-solutions-at-upcoming-us-clinical-conferences-302692311.html

SOURCE BDMD

FAQ

When will Baird Medical (BDMD) present at NASOIE and where is the event?

Baird Medical will present at NASOIE on Feb 27–28, 2026 in Miami. According to the company, the sessions will include live demonstrations and clinician engagement to show MWA thyroid treatment techniques and device use.

What will Baird Medical (BDMD) demonstrate at the NASIT conference in March 2026?

At NASIT Mar 6–7, 2026 in Portland, Baird Medical will demonstrate needle-based MWA for benign thyroid nodules. According to the company, demonstrations aim to educate interventionalists and surgeons on non-surgical, scar-sparing treatment workflows.

Which dates will Baird Medical (BDMD) attend ISITES and what will be the focus?

Baird Medical will attend ISITES Mar 11–13, 2026 in Washington, D.C., focusing on minimally invasive endocrine surgery techniques. According to the company, the focus is clinical demonstrations of its proprietary MWA technology for thyroid care.

How does Baird Medical (BDMD) say its MWA technology benefits patients with benign thyroid nodules?

The company says MWA treats benign nodules without traditional surgery or scarring, offering a less invasive option. According to the company, this approach aims to reduce recovery time while maintaining effective nodule management for appropriate patients.

Will Baird Medical (BDMD) provide hands-on training for clinicians at the conferences?

Baird Medical intends to provide direct clinician access and demonstrations rather than formal certification courses. According to the company, sessions are designed to show device use and clinical workflows to encourage adoption among U.S. physicians.

Why is Baird Medical (BDMD) attending multiple U.S. conferences in early 2026?

The company is attending to drive U.S. adoption of its MWA thyroid therapies through clinician engagement and live demos. According to the company, building direct relationships with the clinical community supports expansion in the U.S. market.